Mogamulizumab 生物类似药, CCR4 单克隆抗体-Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody代理/参数/厂家-二抗-开云·官方站线上登录平台入口

PRODUCT CENTER

二抗

开云·官方站线上登录平台入口_开云(中国)

当前位置：开云·官方站线上登录平台入口 > 开云·官方站线上登录平台入口_开云(中国) > 免疫学产品 > 二抗

中文名称: Mogamulizumab 生物类似药, CCR4 单克隆抗体

英文名字: Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody

供应商: Promab

产品货号: PMB-B00046

产品报价: ￥询价/1mg/5mg/20mg

产品说明书: 点击查看

购买方式: 90%产品中国有现货库存。银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868

产品新闻

背景资料: Mogamulizumab Biosimilar uses the same protein sequences as the therapeutic antibody mogamulizumab.nnMogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions.nnMogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity.nnMogamulizumab selectively binds to and inhibits the activity of CCR4, which may block CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, as well as chemokine-mediated angiogenesis. Additionally, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and certain types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells. In addition to directly targeting malignant T cells expressing CCR4, mogamulizumab depletes Treg cells, an important therapeutic target in many human cancers because of their role in suppressing host antitumor immunity.